{
  "Johnson & Johnson": {
    "2023": {
      "FORM": "8-K",
      "CATEGORIES": {
        "Section 1 - Registrant's Business and Operations": {
          "ITEMS": {
            "Item 1.01 - Entry into a Material Definitive Agreement": {
              "content": "On May 8, 2023, Kenvue Inc., a Delaware corporation (“Kenvue”), completed its previously announced initial public offering (the “IPO”) of 198,734,444 shares of its common stock, par value $0.01 per share (the “Kenvue Common Stock”), including the underwriters’ full exercise of their option to purchase 25,921,884 shares to cover over-allotments, at an initial public offering price of $22.00 per share for net proceeds of $4,241 million. Prior to the IPO, Kenvue was a wholly owned subsidiary of Johnson & Johnson. Pursuant to the Separation Agreement, the net proceeds from the IPO will be paid to Johnson & Johnson as partial consideration for the consumer health business that Johnson & Johnson transferred to Kenvue in connection with the IPO (the “Consumer Health Business”). As of the closing of the IPO, Johnson & Johnson owns 1,716,160,000 shares of Kenvue Common Stock, or approximately 89.6% of the total outstanding shares of Kenvue Common Stock, and will continue to consolidate the financial results of Kenvue.",
              "subsections": {
                "Separation Agreement": "In connection with the IPO and as previously contemplated by, and described in, the Registration Statement on Form S-1, as amended (File No. 333-269115), filed by Kenvue with the Securities and Exchange Commission and declared effective on May 3, 2023 (the “Registration Statement”), Johnson & Johnson and Kenvue entered into a separation agreement (the “Separation Agreement”) on May 3, 2023. The Separation Agreement sets forth certain agreements between Johnson & Johnson and Kenvue regarding, among other matters: the principal corporate actions and internal reorganization pursuant to which Johnson & Johnson transferred the Consumer Health Business to Kenvue; the allocation of assets and liabilities to Johnson & Johnson and Kenvue; Johnson & Johnson’s and Kenvue’s respective rights and obligations with respect to the IPO; certain matters with respect to any subsequent distribution or other disposition by Johnson & Johnson of the shares of Kenvue Common Stock owned by Johnson & Johnson following the IPO (the “Distribution”); and other agreements governing aspects of Kenvue’s relationship with Johnson & Johnson following the IPO. The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is attached hereto as Exhibit 10.1 and incorporated herein by reference.",
                "Related Agreements": "In connection with the IPO and as previously contemplated by, and described in, the Registration Statement, Johnson & Johnson and Kenvue, or subsidiaries of each party, also entered into various other material agreements. These agreements were entered into on May 3, 2023, unless otherwise indicated, and consist of the following: a tax matters agreement, which governs Johnson & Johnson’s and Kenvue’s respective rights, responsibilities and obligations with respect to all tax matters; an employee matters agreement, which addresses certain employment, compensation and benefits matters; an intellectual property agreement, which governs Johnson & Johnson’s and Kenvue’s respective rights, responsibilities and obligations with respect to intellectual property matters; a trademark phase-out license agreement, dated as of April 3, 2023, pursuant to which Johnson & Johnson granted to Kenvue a license to use certain trademarks owned by Johnson & Johnson on a transitional basis; and a registration rights agreement, pursuant to which Kenvue granted to Johnson & Johnson certain registration rights with respect to the shares of Kenvue Common Stock owned by Johnson & Johnson following the completion of the IPO. The foregoing descriptions of these agreements do not purport to be complete and are qualified in their entirety by reference to the full text of these agreements, which are attached hereto as Exhibits 10.2, 10.3, 10.4, 10.5 and 10.6, respectively, and incorporated herein by reference."
              }
            }
          }
        },
        "Section 9 - Financial Statements and Exhibits": {
          "ITEMS": {
            "Item 9.01 - Financial Statements and Exhibits": {
              "content": "(d) Exhibits.",
              "subsections": {
                "Exhibits List": "Exhibit 10.1: Separation Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc.\nExhibit 10.2: Tax Matters Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc.\nExhibit 10.3: Employee Matters Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc.\nExhibit 10.4: Intellectual Property Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc.\nExhibit 10.5: Trademark Phase-Out License Agreement, dated as of April 3, 2023, by and between Johnson & Johnson and Johnson & Johnson Consumer Inc.\nExhibit 10.6: Registration Rights Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc.\nExhibit 104: The cover page from this Current Report on Form 8-K, formatted in Inline XBRL."
              }
            }
          }
        }
      }
    }
  }
}